Sales & PLC of Gleevec

SALES DATA & PLC GRAPH OF

GLEEVEC (NOVARTIS)

Prepared by: Akshay SaxenaSubmitted to: P. S. Rai Chaudhary Sir

NOVARTIS Novartis was created in 1996 through the merger of Ciba-

Geigy and Sandoz.

Joseph Jimenez is the CEO of this company.

Headquarters in Basel, Switzerland.

Mission- Our mission is to care and cure.We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.

NOVARTIS INDIA Novartis is currently ranking 21 in India

(http://pharmatips.doyouknow.in/Articles/Pharma-Companies/List-Of-Top-100-Pharma-Company-In-India.aspx)

Chairman- Christopher Snook

Vice Chairman- Ranjit Shahani

Director- Dr. Rajen Mehrotra

Office- Annie Besant Road, Mumbai, India

THERAPEUTIC AREAS Arthritis/Bone Gastrointestinal Cardiovascular Genetic Diseases Infectious Diseases Neuroscience Oncology Haematology Ophthalmology Respiratory Transplantation, Immunology

Segmentation• Animal health, Diagnostics,

Oncology, CNS drugs, Eye care, Vaccines & Generics

Positioning• To discover, develop and

successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life around the globe.

Target Group• Healthcare professionals• Doctors

1.Has a global reach in over 140 countries2. Core businesses in pharmaceuticals, vaccines, consumer health, generics and animal health.3. Mergers and acquisitions have it a strong brand.4. First company-wide health and well-being initiative at Novartis. Employee strength of over 150,000.

1. Controversies regarding their advertising of certain products affected brand image.

2. Case regarding Indian patent laws also created a problem for the brand.

1. Broad-based medical innovation, in technologies and businesses across the spectrum of health care.2. Venture into health needs in under-developed and poor countries.3. Leverage its core business expertise and resources to create sustainable solutions in countries around the world.

1. Increasing obsolesce of technology.

2. Competition from peers.

SWOT

1. Gleevec is used to treat certain types of leukaemia (blood cancer), bone marrow disorders, skin cancer and certain tumours of the stomach and digestive system.

2. Gleevec (imatinib) interferes with the growth of some cancer cells.

3. Launched in 2001.

4. Patented till 2017.

5. Generated revenue of more than $4.5 Billion.

PRICE OF GLEEVEC IN VARIOUS COUNTRIES

KEY PRODUCT REVENUES

SALES (2011-2014) OF GLEEVEC

Date Range Sales Rank Sales ($) Sales (%) Units (000) Units (%)

Q4 2013 24 $498,149 7.22% 81 3.85%

Q3 2013 25 $464,588 -1.68% 78 -11.36%

Q2 2013 24 $472,509 7.85% 88 7.32%

Q1 2013 26 $438,105 0.41% 82 -5.75%

Q4 2012 26 $436,298 -4.10% 87 -5.43%

Q3 2012 25 $454,935 10.57% 92 9.52%

Q2 2012 34 $411,455 5.21% 84 6.33%

Q1 2012 38 $391,072 0.13% 79 -8.14%

Q4 2011 36 $390,547 4.38% 86 3.61%

Q3 2011 35 $374,171 5.88% 83 -2.35%

Q2 2011 37 $353,382 1.64% 85 1.19%

Q1 2011 40 $347,690 84

PROJECTED SALES

REFERENCES

http://www.drugs.com/stats/gleevec http://www.wikinvest.com/stock/Novartis_AG_%

28NVS%29/Gleevec_Glivec http://

www.novartisoncology.com/products/glivec.jsp www.fda.gov/Drugs/DrugSafety/.../ucm110505.htm www.webmd.com/drugs/2/drug-20980/gleevec

-oral/details

THANK YOU